Creating a Global Company
Sun Pharma today
SUN
PHARMA
US Formulations
9th largest generics company in US* with a strong
pipeline (88 ANDAs & 13 NDAs awaiting approval)
Presence in Specialty branded & generics segments
with more than 560 approved products
FY21 sales: Rs. 100,921 mn
India
33%
FY21
Geographical
sales split
India Branded Generics
No.1 ranked with 11 classes of doctor categories
⚫ Leading position in high growth chronic therapies
Specializes in technically complex products
FY21 sales: Rs. 103,432 mn
Market cap: US$ 29 bn (1)
Gross Sales: Rs. 332,331 mn
EBITDA: Rs. 82,263 mn (24.8% margin)
R&D Investment: 6.5% of Sales
Globalized supply chain
Strong balance sheet
Share
Revenue
Emerging
Markets
18%
Rest of World
(ROW)# 15%
India
Branded
Generics
31%
API & Others
FY21
6%
International
67%
54% owned by promoter group
US
Formulation
30%
Note:
Emerging Markets
Presence in about 80 countries across Africa, Americas,
Asia and Eastern & Central Europe
Key focus markets - Romania, Russia, South Africa, Brazil
& Mexico and complementary & affiliated markets
FY21 sales: Rs. 57,840 mn
(1) As of Mar, 17 2022 using spot exchange rate of INR/USD = 75.81
# Includes Western Europe, Canada, Japan, Australia & New Zealand, Israel and other markets.
All sales numbers in US$ for 12 months ended March 31, 2021
* Source: IQVIA data for 12 months ended December 2021
Rest of World (ROW)
Presence across key markets in Western Europe, Canada,
Japan, Israel, A&NZ and other markets
⚫ Product portfolio includes specialty products, differentiated
offerings for hospitals, injectables & generics for retail market
FY21 sales: Rs. 48,956 mn
6.View entire presentation